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Abstract: Aims of the present investigation were: (i) to assess the prevalence of current 
smokers and relative smoking status among a large number of heroin addicts attending 
opioid-substitution therapy prevalence; (ii) to evaluate the relationship between the type 
(methadone, buprenorphine) and dosage of opioid substitution therapy and nicotine 
dependence. Three hundred and five (305) heroin addicts under opioid-substitution therapy 
were recruited at five Addiction Units. All participants completed a questionnaire assessing 
sociodemographic information, type and dose of opioid-substitution therapy, smoking 
history and status, Fagerström Test for Nicotine Dependence (FTND), and the Zung   
Self-Rating Depression scale (SDS). 298 subjects, out of 305 (97.2%) were smokers, with 
an average of 20.5 cigarette/day and a median FTND of 6. Our data confirmed the high 
prevalence of smokers among heroin addicts, the highest described in the literature to date 
among heroin addicts under substitution therapies, without any significant difference 
OPEN ACCESSInt. J. Environ. Res. Public Health 2012, 9 933 
 
 
between methadone vs. buprenorphine therapy groups. There was no correlation between 
dose of methadone or buprenorphine and average number of cigarettes/day. Patients in 
substance abuse treatment very frequently smoke cigarettes and often die of tobacco-related 
diseases. Substance abuse treatment programs too often ignore tobacco use. We hope that 
these findings will help to incorporate smoking cessation in substance abuse treatments. 
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1. Introduction 
Cigarette smoking prevalence is extremely high, and cessation rates are very low among heroin 
addicted subjects in opioid substitution therapy. There is a large body of anecdotal evidence about the 
association between drug addiction and tobacco smoking, yet despite the amount of literature that has 
been published on this issue, the state of research on tobacco smoking among the subjects in methadone 
treatment is not as developed as it should be (and even less so in buprenorphine treatment). There is 
however the clear need to better understand the relationship between opioids use and cigarette 
consumption. 
Most common key findings about methadone clients are a high prevalence of smoking, generally 
more than 80%, and a very low quitting rate, generally less than 10%. Common, in most studies, is the 
statement that the best medicine for nicotine treatment in methadone and buprenorphine-maintained 
subjects is far from adequate and the need of tailored interventions for this population [1–4].  
Placebo controlled studies confirmed that addictive drugs use or abuse may be associated to an 
increased nicotine intake. For instance, ethanol administration in alcoholics [5] and in non-alcoholic 
social drinkers [6] increased tobacco smoking. Administration of D-amphetamine increased smoking 
behaviour in non-drug abuser smokers, similarly to pentobarbital in ex-drug abuser smokers [7]. Among 
the substances that have been suggested to potentiate nicotine intake, heroin and methadone are of 
particular interest because of their potential reciprocal effect, respectively as drug of abuse and 
substitution drug therapy. Heroin addicted smokers (HAS) smoked more cigarettes when heroin self-
administration was allowed than during heroin-free or under methadone detoxification condition 
periods [8]. Treatment for smoking cessation in this segment of smokers showed low success 
rates [9,10]. It appears that it is more difficult for these individuals to quit smoking than heroin [11].  
It is reported that a high percentage of methadone-maintained patients are tobacco smokers.   
The number of daily smoked cigarettes gradually decreases along with daily methadone maintenance 
dose during a progressive methadone dose reduction period [12]. Chait and Griffiths showed that 
methadone induced a dose-related increase of smoking [13]. Methadone and nicotine have been shown 
to decrease restlessness, irritability, and depression [14]. Methadone has been shown to influence 
timing and smoking rate in a dose dependent correlation [15]. Cigarette smoking rates are higher in the 
methadone-maintained opiate-dependent people than in the general population [16,17]. At least 80% of 
methadone patients smoke [2,18]. Similarly, opioid substitution therapy with buprenorphine showed 
increased smoking rates [19,20]. Recently, it was reported that methadone and nicotine interaction in 
methadone-maintained patients enhances ratings of euphoria and drug liking [4].  Int. J. Environ. Res. Public Health 2012, 9 934 
 
 
The relationship between the type and dosage of opioid substitution therapy and smoking status, as 
well as the potential role of other biological and psychosocial variables such as gender, age, psychiatric 
co-morbidities, etc., is currently unclear. Some studies have implicated methadone as a determinant 
factor, e.g., increasing methadone dose increases smoking [11,13]. The methadone/nicotine interaction is 
very complex [21], further complicated by habituation seen at higher methadone doses [1]. Despite this 
body of literature describing the associations between methadone, buprenorphine, and nicotine, it 
should be noted that most of these experimental studies have been performed in research laboratories 
and with limited follow-up. One thing is to observe the correlates of smoking in a laboratory, and quite 
another is to observe smoking habit in daily living environment. 
Therefore, more data are needed on the methadone/nicotine interaction in order to possibly revise 
dose regimen and protocols for methadone substitution therapy, or for other opioid substitution therapy 
such as that with buprenorphine.  
2. Objectives 
The scope of the present cross-sectional investigation was primarily to assess the prevalence of 
current smokers and relative smoking status (i.e., number of cigarettes, nicotine dependence, quit 
attempts, smoking free periods, etc.) among a large number of heroin addicts attending opioid-substitution 
therapy. Secondly, to evaluate the relationship between the type (methadone or buprenorphine) and 
dosage of opioid substitution therapy and nicotine dependence.  
Smoking is often considered acceptable for patients under methadone or buprenorphine therapy, 
who are rarely encouraged to quit smoking or supported in their efforts to quit. It’s commonly assumed 
that HAS are very hard smokers, that quitting smoking will worsen their psychiatric symptoms, or that 
HAS do not want to quit smoking. 
3. Methods 
3.1. Study Participants 
A total of 305 heroin addicts participants under opioid substitution therapy (298 current smokers, 
seven non-smokers) participated in the study. The heroin addicts were already assigned to substitution 
treatment when the study began. Most of participants were male (82.3%) and averaged 34.5 (±7.0) 
years of age (Table 1). Subjects were eligible for participation if they were heroin addicts   
under opioid-substitution therapy with methadone or buprenorphine. Exclusion criteria were: (i) other 
than heroin addiction; (ii) heroin addiction under treatment with opioid antagonists, or with   
non-pharmacological therapy. Recruitment was done at five Addiction Units (Servizio per le 
Dipendenze, Ser.D) localized in North-East Italy (Bussolengo, Legnago, Bolzano, Castelfranco 
Veneto, Vicenza). Ser.D are outpatient clinics, providing treatment at no cost to patients. There are 
about 200 such centres in Northern Italy: each Ser.D has a multi-disciplinary staff including doctors, 
nurses, psychologists and social workers and is generally able to provide medical and psychosocial 
support. Most of patients in care are heroin users. Int. J. Environ. Res. Public Health 2012, 9 935 
 
 
Table 1. Characteristics for study participants under opioid substitution therapy. Number 
and prevalence for demographic, type of opioid substitution, depressive symptoms and 
smoking status.  
Variables 
Non-smokers 
N (%) 
a 
Smokers 
N (%) 
a 
Totals 
N (%) 
Number  7 (2.8)  298 (97.2)  305 (100) 
Mean age in years (SD)  38.9 (8.4)  34.4 (6.9)  34.5 (7.0) 
Gender 
Male 
Female 
 
3 (42.9) 
4 (57.1) 
 
248 (83.2) 
50 (16.8) 
 
251 (82.3) 
54 (17.7) 
Marital status 
Unmarried 
Married 
Separated or Divorced 
Widowed 
 
4 (57.1) 
2 (28.6) 
1 (14.3) 
0 (0.0) 
 
202 (67.8) 
63 (21.1) 
30 (10.1) 
3 (1.0) 
 
206 (67.5) 
65 (21.3) 
31 (10.2) 
3 (1.0) 
Lives with smokers 
No 
Yes 
 
3 (42.9) 
4 (57.1) 
 
106 (35.6) 
192 (64.4) 
 
109 (35.7) 
196 (64.3) 
Opioid therapy 
Methadone 
Buprenorphine 
 
4 (57.1) 
3 (42.9) 
 
204 (68.5) 
94 (31.5) 
 
208 (68.2) 
97 (31.8) 
Depressive symptoms (SDS score) 
No (<50 pts) 
Yes (50 pts) 
 
5 (71.4) 
2 (28.6) 
 
135 (45.3) 
163 (54.7) 
 
140 (45.9) 
165 (54.1) 
In italic: mean and SD values. Abbreviations: N = number; pts = points; SD = standard deviation; 
SDS = Zung Self-Rating Depression Scale. 
a = percentage of values in column “Totals”. 
None of HAS were under concomitant smoking cessation intervention at the time of the survey. No 
pay was provided for participants in the study. 
3.2. Procedure 
All participants gave written informed consent to participate. The procedure was approved by   
the local ethical authority (the Ethical Committee of University Hospital of Verona). The   
participants completed a questionnaire assessing social-demographic information, type and dose of 
opioid-substitution therapy, some information about smoking history and status, Fagerström Test   
for Nicotine Dependence (FTND) [22] and, the Zung Self-Rating Depression scale (SDS) for   
self-assessment of depressive symptoms [23]. FTND is the most validated and used tool to measure 
the degree of nicotine dependence. It is easy to understand and it takes only few minutes for the  
self-compilation. In addition, the FTND is very accurate for medium and high degrees of dependency, 
less for lower levels of smoking (floor effect) [22]. To assess depression symptoms we opted for the 
SDS because it’s a very simple tool, quick (20 items, overall) and self-administrated [24]. To increase 
the reliability tests were completely anonymous (as well as socio-demographic data), so they must be 
either self-administered.  Int. J. Environ. Res. Public Health 2012, 9 936 
 
 
3.3. Data Analysis 
Categorical variables were compared by bivariate statistical analysis with Chi-square test, or with 
Fisher’s exact test. Comparisons between continuous variables vs. type of opioid-substitution therapy, 
or between type of smokers (HAS vs. n-HAS) were done by Student’s t-test. The Pearson's correlation 
coefficient was use to analyze correlations between continuous variables. Multivariate analysis was 
performed by using two logistic regression models, the first with type of opioid-substitution therapy  
as a dependent variable, the second with type of smoker as a dependent variable. Alpha was set at  
0.05 (two-tailed) for all statistical analyses, which were performed by using SPSS 11.5 statistical 
software (SPSS 11.5, SPSS Inc., Chicago, IL, USA). 
4. Results 
4.1. Characteristics and Smoking Prevalence for Participants under Opioid Substitution Therapy 
As expected in the heroin addicted population, most of the participants were current smokers (97.2%), 
with 64.3% of them additionally living with smokers. All non-smoker participants self-reported to be 
never-smokers. All the participants were under opioid-maintained therapy, with about 68.5% or more 
than two thirds of the 298 smokers under treatment with methadone and 31.8% with buprenorphine. 
Median dose was 40 mg/day for methadone (95% CI 10.00–147.75 mg/day) and 6 mg/day for 
buprenorphine (95% CI 1.0–45.5 mg/day). About half of the sample (54.1%) showed depressive 
symptoms according to the criteria of SDS. 
4.2. Correlations Between Tobacco Addiction and Type of Opioid-Substitution Therapy for Heroin 
Addicted Smokers  
Among the 298 HAS under opioid-substitution participants under methadone were significantly 
older than those with buprenorphine (35.1% vs. 32.9%, p = 0.013). There were not significant 
differences in allocation to type of opioid-substitution therapy between males and females (Table 2).  
Table 2. Bivariate analysis between tobacco addiction and type of opioid-substitution 
therapy. Number and prevalence for demographic, depressive symptoms, nicotine 
dependence, smoking status, smoking history and type of opioid substitution. 
Variables 
Methadone 
N (%) 
a 
Buprenorphine 
N (%) 
a 
Totals 
N (%) 
P 
Number  204 (68.5)  94 (31.5)  298  
Mean age in years (SD)  35.1 (7.0)  32.9 (6.5)  34.4 (6.9)  0.013 
Gender 
Male 
Female 
 
170 (83.3) 
34 (16.7) 
 
78 (83.0) 
16 (17.0) 
 
248 (83.2) 
50 (16.8) 
 
 
n.s. 
Marital status 
Unmarried 
Married 
Separated or Divorced 
Widowed 
 
135 (66.2) 
43 (21.1) 
23 (11.3) 
3 (1.5) 
 
67 (71.3) 
20 (21.3) 
7 (7.4) 
- (0.0) 
 
202 (67.8) 
63 (21.1) 
30 (10.1) 
3 (1.0) 
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Table 2. Cont. 
Variables 
Methadone 
N (%) 
a 
Buprenorphine 
N (%) 
a 
Totals 
N (%) 
P 
Depressive symptoms (SDS score) 
No (<50  pts) 
Yes (50 pts) 
 
83 (40.7) 
121 (59.3) 
 
52 (55.3) 
42 (44.7) 
 
135 (45.3) 
163 (54.7) 
 
0.013 
Nicotine dependence (FTND score, pts) 
Very low  (0–2) 
Low (3–4) 
Medium (5–6) 
High (7–8) 
Very high  (9–10) 
 
34 (16.7) 
40 (19.6) 
60 (29.4) 
49 (24.0) 
21 (10.3) 
 
9 (9.6) 
25 (26.6) 
28 (29.8) 
21 (22.3) 
11 (11.7) 
 
43 (14.4) 
65 (21.8) 
88 (29.5) 
70 (23.5) 
32 (10.7) 
 
n.s. 
Average N cigarettes/day (SD)  20.6 (10.1)  20.2 (8.0)  20.5 (9.5)  n.s. 
Average smoking years (SD)  19.9 (7.6)  17.0 (7.1)  19.0 (7.5)  0.003 
N self-reported quit attempts  
0 
1 
1 
 
123 (60.3) 
26 (12.7) 
55 (27.0) 
 
50 (53.2) 
21 (22.3) 
23 (24.5) 
 
173 (58.1) 
47 (15.8) 
78 (26.2) 
 
n.s. 
Lives with smokers 
No 
Yes 
 
64 (31.4) 
140 (68.6) 
 
42 (44.7) 
52 (55.3) 
 
106 (35.6) 
192 (64.4) 
 
0.026 
In  italic: mean and SD values. Abbreviations: FTND = Fagerström Test for Nicotine Dependence;  
N = number; n.s. = not statistically significant; pts = points; SD = standard deviation; SDS = Zung  
Self-Rating Depression Scale; 
a = percentage of values in column “Totals”. 
Participants under methadone showed more depressive symptoms than those under buprenorphine 
substitution therapy (59.3% vs.44.7%; p = 0.018). 
Degree of nicotine dependence, smoking status and history parameters (FTND score, average 
number of cigarettes/day, number of self-reported quit attempts; number of self-reported abstinence 
periods greater than 6 months (Table 2) were not significantly different between methadone and 
buprenorphine substitution groups. The only difference was a longer smoking history (19.9 vs.  
17.0 years; p = 0.03) and a greater number of participants living with smokers in the methadone vs. the 
buprenorphine substitution group (68.6% vs. 55.3%; p = 0.026). 
There was no correlation between dose of opioid-substitution therapy and average number of 
cigarettes/day, respectively −0.055 for methadone and 0.105 for buprenorphine (both with p > 0.05; 
Pearson’s correlation coefficient). 
Logistic regression analysis showed an independent association between type of opioid-substitution 
therapy and smoking parameters (Table 3): (i) greater number of subjects under methadone therapy 
living with smokers (OR 0.57, 95% CI 0.33–0.98; p = 0.040); (ii) a lower degree of correlation between 
very low level of nicotine dependence (0–2 points, FTND score) and buprenorphine therapy (OR 0.25, 
95% CI 0.07–0.96; p = 0.044). Int. J. Environ. Res. Public Health 2012, 9 938 
 
 
Table 3. Logistic regression analysis between type of opioid-substitution therapy and 
smoking parameters. 
Variables OR  95%  CI    P 
Nicotine dependence (FTND score, pts) 
Very low  (0–2) 
 
0.25 
 
0.07–0.96 
 
0.044 
Living with smokers 
Yes 
 
0.57 
 
0.33–0.98 
 
0.040 
Abbreviations: CI = confidence intervals; FTND = Fagerström Test for Nicotine Dependence;   
OR = Odd Ratio; pts = points; Abbreviations: CI = confidence intervals; OR = Odd Ratio;   
SDS = Zung Self-Rating Depression Scale; pts = points. 
5. Discussion 
This multicentre cross-sectional study confirmed the very high prevalence of tobacco addiction in 
heroin addicts under opioid-substitution therapy. Prevalence data were greater than those reported in 
similar samples [3–18], and more than three-fold higher compared to the prevalence in the matching 
Italian general population (OSSFAD, 2010) [25]. Furthermore, prevalence data came out the same than 
those described among Italian heroin users [26]. These data raise a concern previously reported in the 
literature: the lack of promotion that smoking cessation finds among the substance abuse treatment 
programs. It’s rather surprising that the prevalence of current smokers in the five centres evaluated is 
the same as that observed in Italian heroin users. Furthermore, it should be noted that none of the  
non-smokers heroin addicted patients had stopped smoking. All seven cases were never smokers. 
These data underline the lack of action against smoking in opioid substitution programs and, on the 
other hand, the difficulty to quit smoking without an effective support for these subjects.  
The main question is whether the substitution therapy may interfere with smoking status. Our study 
showed that there was no difference between types of opioid substitution therapy (methadone, a full 
opioid agonist vs. buprenorphine, a partial agonist one) as far as concerns nicotine dependence and 
smoking status (in particular, no significant correlation between dose of methadone or buprenorphine 
and number of cigarette/day), suggesting that opioid substitution therapy did not have any apparent 
effect. This is an important finding: tobacco smoking is the first avoidable cause of death in developed 
countries and the possibility that high doses of methadone or buprenorphine can enhance nicotine 
dependence could raise an ethical debate over substitution treatments, at least for those at higher 
dosage and for prolonged times.  
However, we cannot exclude that there is a reciprocal interaction between nicotine and the   
opioid substitution drugs. It was postulated that the two substances (nicotine and methadone) may 
reciprocally alleviate withdrawal effects [4], as it was shown by dose comparison studies by Spiga and 
colleagues [21,27]. It is also noteworthy that there was not apparent interaction between methadone 
and nicotine taken as a substitution therapy for smoking cessation (nicotine replacement therapy, NRT) 
as shown by Shoptaw et al. [9] and Stein et al. [10]. Therefore, the hypothetical interaction between 
methadone and nicotine might take place under specific conditions of dosage and exposure (e.g., smoked 
nicotine and not NRT) and its effects might be evident only on some symptomatic dimensions of tobacco 
addiction [28].  Int. J. Environ. Res. Public Health 2012, 9 939 
 
 
HAS had a not negligible number of self-reported quit attempts and rates of smoking abstinence for 
periods longer than 6 months. These data are in contrast with a low success rate in smokers under 
methadone substitution therapy [9], but this could suggest that these subjects may be motivated to quit. 
In fact, several studies reported that heroin addicts under methadone-substitution therapy are willing to 
quit smoking [2,29–31]. On the other hand, the longer smoke-free periods showed by HAS could be 
also due to periods of stay in rehab facility, hospital or jail. 
SDS data show a significant rate of depressive symptoms in the HAS smokers (54.7%). Depressive 
symptoms prevalence in this group is difficult to compared to other data, taken from the general 
population. WHO reported 7.8–9% prevalence of depressive symptoms in the Italian population [32]. 
The depressive co-morbidity is a factor worsening patient clinical profile and success rate for smoking 
cessation in heroin addicts under methadone substitution therapy [33,34]. Mood disorders should 
carefully investigated all along smoking cessation treatment when HAS seek treatment to quit smoking.  
Logistic regression analysis showed that a greater number of subjects under methadone therapy was 
living with smokers. In Italy males heroin addicts are often in stable relationships with females without 
histories of drug addiction [35]. This phenomenon is more represented among buprenorphine-maintained 
patients, usually affected by a less severe addiction than methadone-maintained ones [36,37]. The partners 
of heroin addicts without drug histories are less likely to be smokers. This reason can maybe explains the 
correlation between very low level of nicotine dependence and buprenorphine therapy. 
However our study presents some limitations. Data about the presence of polydrug abuse and of 
other co-morbidities weren’t registered. This information, together with a more detailed description of 
opioid substitution therapy duration, could have been informative in order to identify novel factors that 
may play a relevant role in the management of heroin addicted smokers under opioid substitution 
therapy. Furthermore, the assignment to methadone and buprenorphine substitution therapy was not 
performed with random criteria.  
Conclusions 
In conclusion, our report suggests the safety of opioid substitution therapy as far as tobacco 
addiction is concerned: higher doses of methadone or buprenorphine don’t automatically lead patients 
to smoke more. We did not observe a dose-related correlation between nicotine dependence and 
smoking behaviour in methadone and buprenorphine maintained subjects. However, we recommend 
that smoking status should be accurately monitored in heroin addicts accessing therapeutic 
intervention, and that smoking cessation should be always proposed to these patients. Considering  
that they are willing to quit smoking, even if it is more difficult than for the smoking general   
population [33,38,39], smoking cessation intervention should be taken in high priority consideration.  
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